首頁 > 市場調查報告書 > 製藥

生物製劑

市場調查報告書

商品編碼

1845759

2024 年至 2031 年重組蛋白市場規模（按產品類型、應用、最終用戶和地區分類）

Recombinant Proteins Market Size by Product Type, Application, End-User and Region for 2024-2031

出版日期: 2025年09月14日 | 出版商:

Verified Market Research | 英文 202 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

重組蛋白市場評估 - 2024-2031

受生物製藥需求成長、蛋白質工程技術進步以及在治療和診斷領域應用不斷拓展的推動，重組蛋白市場正在經歷顯著成長。重組蛋白有望提供副作用較少的標靶治療，從而刺激市場擴張。慢性病盛行率上升、蛋白質體學研究投入增加以及人工智慧在蛋白質設計和生產中的應用進一步推動了這一成長。預計這些因素將推動市場規模在2024年超過2.686億美元，到2031年達到約5.3677億美元。

除了這些成長要素外，研發投入也不斷增加，旨在開發功能增強的新型重組蛋白。專注於改進蛋白質表現系統和擴大生產流程，為市場擴張開闢了新的途徑，尤其是在提高產量和成本效益方面。此外，新興國家對重組蛋白的日益普及以及受託製造廠商的興起，正在推動各地區市場的成長。對重組蛋白治療和診斷產品日益成長的需求預計將推動市場在2024年至2031年間以9.04%的複合年成長率成長。

定義/摘要

重組蛋白是利用重組DNA技術生產的蛋白質。該技術涉及將編碼特定蛋白質的基因插入宿主生物體，然後表達該蛋白質。重組蛋白因其高純度、一致性和擴充性而被廣泛應用於研究、診斷和治療領域。該技術可以生產難以或無法從天然來源獲得足夠數量的蛋白質。

重組蛋白技術正在生命科學產業的各個領域開發和應用。在生物製藥領域，它有助於開發針對各種疾病的標靶治療。在研究應用中，它有助於研究蛋白質的功能和相互作用。在診斷領域，重組蛋白解決方案可以提高檢測的特異性和靈敏度。

重組蛋白市場前景光明，新技術和新應用具有成長潛力。更先進的蛋白質工程技術的發展以及合成生物學方法的整合預計將帶來新的市場機會。無細胞蛋白質合成技術的進步以及生產複雜多結構域蛋白質的可能性，或將帶來更多樣化和高效的重組蛋白產品。

生物製藥需求的不斷成長將如何推動重組蛋白市場的成長？

生物製藥需求的不斷成長是重組蛋白市場成長的主要驅動力。隨著全球醫療保健系統轉向使用生技藥品治療癌症、自體免疫疾病和遺傳性疾病等慢性複雜疾病，高品質治療性蛋白質的需求呈爆炸性成長。重組蛋白在這一趨勢中發揮關鍵作用，它能夠提供符合嚴格監管標準的、一致性、可擴展且高度特異性的蛋白質療法。

重組技術能夠生產多種蛋白質，包括單株抗體、生長因子、荷爾蒙和酶，這些對於創新藥物和治療方法的開發至關重要。這種多功能性使重組蛋白在治療應用和研究環境中都至關重要，包括疫苗開發和細胞培養過程。此外，包括哺乳動物、細菌和酵母平台在內的表達系統的進步提高了生產效率、純度和產量。對個人化醫療和標靶治療的日益關注也促使製藥和生物技術公司大力投資重組蛋白生產。這種趨勢，加上研發活動的活性化和產業參與者之間的合作，正在刺激技術創新並擴大全球重組蛋白市場。

高生產成本的挑戰如何影響重組蛋白市場的成長？

重組蛋白技術高的生產成本是影響重組蛋白市場成長的關鍵挑戰。重組蛋白生產需要複雜的過程，包括細胞培養、蛋白質表現、純化和品管，所有這些都需要專門的設備、熟練的人員和嚴格的法規遵循。這些因素增加了製造成本，使公司難以開發出負擔得起的治療方法，特別是在成本控制是優先事項的新興市場。擴大商業用途的生產規模進一步增加了複雜性，因為在大規模生產中保持一致性、純度和生物活性既具有挑戰性又昂貴。這阻礙了重組蛋白治療方法的廣泛應用，特別是在醫療預算有限的地區。此外，降低全球醫療成本的壓力正促使製藥公司探索更有效率、永續的生產方法，包括製程最佳化、自動化和替代表達系統，如植物性和微生物平台。

概述
北美洲
- 美國重組蛋白市場
- 加拿大重組蛋白市場
歐洲
- 德國重組蛋白市場
- 英國重組蛋白市場
- 法國重組蛋白市場
- 義大利重組蛋白市場
- 西班牙重組蛋白市場
亞太重組蛋白市場
- 中國重組蛋白市場
- 日本重組蛋白市場
- 印度重組蛋白市場
- 澳洲重組蛋白市場
- 韓國蛋白質市場
世界其他地區
- 拉丁美洲重組蛋白市場
- 巴西重組蛋白市場
- 阿根廷重組蛋白市場
中東和非洲重組蛋白市場
- 阿拉伯聯合大公國的重組蛋白市場

第9章：全球重組蛋白市場競爭格局

概述
各公司市場排名
主要發展策略

第10章：公司簡介

Aviva Systems Biology Corporation
StressMarq Biosciences Inc.
United States Biological
ProteoGenix
Icosagen AS
Richcore Lifesciences Pvt Ltd.
ProSpec-TechnoGene Ltd.
ACROBiosystems
CellGenix GmBH
RayBiotech Inc.

第11章公司簡介附錄

相關調查

簡介目錄

Product Code: 129371

Recombinant Proteins Market Valuation- 2024-2031

The Recombinant Proteins market is experiencing significant growth driven by increasing demand for biopharmaceuticals, advancements in protein engineering technologies, and rising applications in therapeutic and diagnostic fields. The potential for recombinant proteins to provide targeted therapies with fewer side effects continues to fuel market expansion. This growth is further bolstered by the rising prevalence of chronic diseases, increasing investment in proteomics research, and the integration of artificial intelligence in protein design and production. This is likely to enable the market size to surpass USD 268.6 Million valued in 2024 to reach a valuation of around USD 536.77 Million by 2031.

In addition to these growth factors, the market is witnessing increased investment in research and development aimed at developing novel recombinant proteins with enhanced functionalities. The focus on improving protein expression systems and scaling up production processes is opening new avenues for market expansion, particularly for enhanced yield and cost-effectiveness. Moreover, the growing adoption of recombinant proteins in emerging economies and the rise of contract manufacturing organizations are driving regional market growth. The rising demand for recombinant protein-based therapies and diagnostics is enabling the market to grow at a CAGR of 9.04% from 2024 to 2031.

Definition/Overview

Recombinant Proteins refer to proteins produced using recombinant DNA technology. This involves inserting a gene that codes for a specific protein into a host organism, which then expresses the protein. Recombinant proteins are widely used in research, diagnostics, and therapeutics due to their high purity, consistency, and scalability of production. This technology allows for the production of proteins that may be difficult or impossible to obtain from natural sources in sufficient quantities.

Recombinant protein technologies are being developed and utilized across various areas of the life sciences industry. In biopharmaceutical production, they help create targeted therapies for various diseases. For research applications, they assist in studying protein functions and interactions. In the realm of diagnostics, recombinant protein solutions enhance the specificity and sensitivity of tests.

The future scope of the Recombinant Proteins market is promising, with potential for growth in emerging technologies and applications. The development of more sophisticated protein engineering techniques and the integration of synthetic biology approaches are expected to open new market opportunities. Advancements in cell-free protein synthesis and the potential for producing complex multi-domain proteins may lead to more diverse and effective recombinant protein products.

How does the Increasing Demand for Biopharmaceuticals Drive the Growth of The Recombinant Proteins Market?

The increasing demand for biopharmaceuticals is a major driver of growth in the Recombinant Proteins Market. As healthcare systems worldwide shift toward biologics for the treatment of chronic and complex diseases, including cancer, autoimmune disorders, and genetic conditions, the need for high-quality therapeutic proteins has surged. Recombinant proteins play a crucial role in this trend by providing consistent, scalable, and highly specific protein-based therapeutics that meet stringent regulatory standards.

Recombinant technology enables the production of a wide variety of proteins, such as monoclonal antibodies, growth factors, hormones, and enzymes, which are essential for developing innovative drugs and therapies. This versatility makes recombinant proteins indispensable in both therapeutic applications and research settings, including vaccine development and cell culture processes. Additionally, advancements in expression systems, such as mammalian, bacterial, and yeast platforms, are enhancing production efficiency, purity, and yield. The increasing focus on personalized medicine and targeted therapies is also driving pharmaceutical and biotechnology companies to invest heavily in recombinant protein production. This trend, coupled with rising R&D activities and partnerships between industry players, is fostering innovation and expanding the global recombinant proteins market.

How is the Challenge of High Production Costs Impacting the Growth of The Recombinant Proteins Market?

The high production costs associated with recombinant protein technology are a significant challenge impacting the growth of the Recombinant Proteins Market. Producing recombinant proteins involves complex processes, such as cell culture, protein expression, purification, and quality control, all of which require specialized equipment, highly skilled personnel, and stringent regulatory compliance. These factors drive up manufacturing costs, making it difficult for companies to develop affordable therapies, particularly in markets where cost containment is a priority. Scaling up production for commercial use adds further complexity, as maintaining consistency, purity, and bioactivity at larger scales is both challenging and expensive. This poses barriers to the widespread adoption of recombinant protein-based therapies, especially in regions with limited healthcare budgets. Additionally, the pressure to reduce healthcare costs globally is pushing pharmaceutical companies to explore more efficient and sustainable production methods, such as process optimization, automation, or alternative expression systems like plant-based or microbial platforms.

Category-wise Acumens

How will the Adoption of Mammalian Expression Systems Drive the Growth of the Growth Factors Segment in Recombinant Proteins?

The adoption of mammalian expression systems is driving significant growth in the Growth Factors segment of the recombinant proteins market. Growth factors, such as erythropoietin, insulin-like growth factors, and granulocyte colony-stimulating factors (G-CSFs), are essential for a variety of therapeutic applications, including tissue regeneration, wound healing, and cancer treatment. As demand for these complex proteins increases, mammalian expression systems have become the preferred production platform due to their ability to perform critical post-translational modifications.

Mammalian systems, such as Chinese hamster ovary (CHO) cells, provide high biological similarity to native human proteins, ensuring improved efficacy and reducing the risk of immunogenic responses in patients. This alignment with therapeutic needs is enhancing interest in and development of recombinant growth factors produced using these systems. Additionally, advancements in cell line development, bioprocess optimization, and scalable bioreactors are improving production yields and cost-efficiency, further accelerating the adoption of mammalian platforms.

How will the Growth of Regenerative Medicine Drive the Expansion of The Research & Development Application Segment?

The growth of the Research & Development Application Segment will be driven by the rapid expansion of regenerative medicine. Factors such as the increasing focus on stem cell research, the need for novel tissue engineering approaches, and the desire for more effective regenerative therapies will contribute to this trend. Recombinant proteins for research and development will be sought to provide efficient and versatile tools for studying cellular processes, developing new therapies, and advancing regenerative medicine technologies.

Increased investment in recombinant protein research will be witnessed, enabling scientists to improve their understanding of cellular biology, develop new drug targets, and enhance regenerative medicine protocols. The research & development application segment will benefit from the integration of advanced protein engineering techniques and improved production technologies, allowing for the creation of more diverse and functional recombinant proteins for research purposes, which will ultimately propel market expansion.

Country/Region-wise Acumens

Will the Presence of Major Biopharmaceutical Companies Drive the Dominance of North America in The Recombinant Proteins Market?

The dominance of North America in the recombinant proteins market is largely driven by the presence of major biopharmaceutical companies and well-established research infrastructures. The United States and Canada are home to some of the world's largest biotechnology and pharmaceutical firms, which play a pivotal role in advancing protein engineering, production technologies, and therapeutic development. These companies not only drive innovation but also establish partnerships with research institutions, fostering a collaborative ecosystem that accelerates the adoption and commercialization of recombinant proteins. North America's strong focus on drug discovery, personalized medicine, and life sciences research further reinforces its leadership in the market. The region's early embrace of biotechnology, combined with substantial investment in R&D, has positioned it at the forefront of breakthroughs in recombinant protein production. Favorable regulatory frameworks and extensive healthcare spending also support the development and deployment of recombinant protein-based therapies, ensuring widespread availability and market growth.

Will the Rapid Growth of the Biotechnology Sector Drive the Expansion of The Recombinant Proteins Market in Asia-Pacific?

The rapid growth of the biotechnology sector is a key driver of the expansion of the Recombinant Proteins Market in Asia-Pacific. With some of the world's fastest-growing economies and a large share of the global population, the region is well-positioned to embrace innovative biotechnology solutions. Governments and private investors are increasingly investing in life sciences research to address evolving healthcare needs, including the rising prevalence of chronic diseases such as cancer, diabetes, and cardiovascular disorders. This trend is generating significant demand for recombinant protein-based therapies, diagnostics, and research tools. Countries like China, India, and South Korea are witnessing substantial growth in their biotechnology industries, supported by favorable policies, expanding research infrastructure, and increasing R&D activities. The region's growing biopharmaceutical manufacturing capabilities further enable cost-effective production of recombinant proteins, attracting partnerships and investments from global pharmaceutical companies. This synergy between a booming biotechnology sector, rising healthcare demands, and a large consumer base is accelerating the adoption of recombinant protein technologies in both therapeutic and research applications.

Competitive Landscape

The recombinant proteins market is a dynamic and competitive space, characterized by a diverse range of players vying for market share. These players are on the run for solidifying their presence through the adoption of strategic plans such as collaborations, mergers, acquisitions and political support. The organizations are focusing on innovating their product line to serve the vast population in diverse regions.

Some of the prominent players operating in the recombinant proteins market include:

Thermo Fisher Scientific, Inc.

Merck KGaA

GenScript Biotech Corporation

Eli Lilly and Company

Abcam plc

Novo Nordisk A/S

Hoffmann-La Roche Ltd

Amgen Inc.

Novartis AG

Biogen Inc.

Latest Developments

In March 2024, Thermo Fisher Scientific, Inc. launched a new high-yield recombinant protein production platform, significantly improving the efficiency and cost-effectiveness of large-scale protein manufacturing.

In June 2024, Merck KGaA successfully implemented an AI-powered protein design platform, demonstrating enhanced capabilities in developing novel recombinant proteins with improved functionalities.

In April 2024, GenScript Biotech Corporation introduced a novel recombinant protein library for CRISPR-Cas9 applications, catering to the growing demand for gene editing tools in research and therapeutics.

In August 2024, Eli Lilly and Company secured a major contract to supply its innovative recombinant insulin analogs for a national diabetes management program in a large Asian country, marking a significant step towards more accessible and effective diabetes treatments.

Recombinant Proteins Market, by Category

Product Type:

Growth Factors

Hormones

Enzymes

Antibodies

Others (Cytokines, Coagulation Factors)

Application:

Biopharmaceutical Production

Research & Development

Diagnostics

Others (Industrial Enzymes, Agriculture)

End-User:

Pharmaceutical & Biotechnology Companies

Academic & Research Institutes

Contract Research Organizations (CROs)

Others (Diagnostic Laboratories, Food & Beverage Industry)

Region:

North America

Europe

Asia-Pacific

Latin America

Middle East and Africa

1 INTRODUCTION OF GLOBAL RECOMBINANT PROTEINS MARKET

1.1 Overview of the Market
1.2 Scope of Report
1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

3.1 Data Mining
3.2 Validation
3.3 Primary Interviews
3.4 List of Data Sources

4 GLOBAL RECOMBINANT PROTEINS MARKET OUTLOOK

4.1 Overview
4.2 Market Dynamics
- 4.2.1 Drivers
- 4.2.2 Restraints
- 4.2.3 Opportunities
4.3 Porters Five Force Model
4.4 Value Chain Analysis

5 GLOBAL RECOMBINANT PROTEINS MARKET, BY PRODUCT

5.1 Overview
5.2 Immune Response Proteins
5.3 Structural Proteins
5.4 Membrane Proteins
5.5 Kinase Proteins
5.6 Regulatory Proteins
5.7 Others

6 GLOBAL RECOMBINANT PROTEINS MARKET, BY APPLICATION

6.1 Overview
6.2 Academic Research Studies
6.3 Biotechnology Research
6.4 Biopharmaceutical Production
6.5 Drug Discovery & Development
6.6 Others

7 GLOBAL RECOMBINANT PROTEINS MARKET, BY END-USER

7.1 Overview
7.2 Contract Research Organizations
7.3 Academic Research Institutes
7.4 Biotechnology Companies
7.5 Pharmaceutical & Biopharmaceutical Companies
7.6 Others

8 GLOBAL RECOMBINANT PROTEINS MARKET, BY GEOGRAPHY

8.1 Overview
8.2 North America
- 8.2.1 United States Recombinant Proteins Market
- 8.2.2 Canada Recombinant Proteins Market
8.3 Europe
- 8.3.1 Germany Recombinant Proteins Market
- 8.3.2 United Kingdom Recombinant Proteins Market
- 8.3.3 France Recombinant Proteins Market
- 8.3.4 Italy Recombinant Proteins Market
- 8.3.4 Spain Recombinant Proteins Market
8.4 Asia Pacific Recombinant Proteins Market
- 8.4.1 China Recombinant Proteins Market
- 8.4.2 Japan Recombinant Proteins Market
- 8.4.3 India Recombinant Proteins Market
- 8.4.4 Australia Recombinant Proteins Market
- 8.4.5 South Korea Proteins Market
8.5 Rest of the World
- 8.5.1 Latin America Recombinant Proteins Market
- 8.5.2 Brazil Recombinant Proteins Market
- 8.5.3 Argentina Recombinant Proteins Market
8.6 Middle East And Africa Recombinant Proteins Market
- 8.6.1 United Arab Emirates Recombinant Proteins Market

9 GLOBAL RECOMBINANT PROTEINS MARKET COMPETITIVE LANDSCAPE

9.1 Overview
9.2 Company Market Ranking
9.3 Key Development Strategies

10 COMPANY PROFILES

10.1 Aviva Systems Biology Corporation
- 10.1.1 Overview
- 10.1.2 Financial Performance
- 10.1.3 Product Outlook
- 10.1.4 Key Developments
10.2 StressMarq Biosciences Inc.
- 10.2.1 Overview
- 10.2.2 Financial Performance
- 10.2.3 Product Outlook
- 10.2.4 Key Developments
10.3 United States Biological
- 10.3.1 Overview
- 10.3.2 Financial Performance
- 10.3.3 Product Outlook
- 10.3.4 Key Developments
10.4 ProteoGenix
- 10.4.1 Overview
- 10.4.2 Financial Performance
- 10.4.3 Product Outlook
- 10.4.4 Key Developments
10.5 Icosagen AS
- 10.5.1 Overview
- 10.5.2 Financial Performance
- 10.5.3 Product Outlook
- 10.5.4 Key Developments
10.6 Richcore Lifesciences Pvt Ltd.
- 10.6.1 Overview
- 10.6.2 Financial Performance
- 10.6.3 Product Outlook
- 10.6.4 Key Developments
10.7 ProSpec-TechnoGene Ltd.
- 10.7.1 Overview
- 10.7.2 Financial Performance
- 10.7.3 Product Outlook
- 10.7.4 Key Developments
10.8 ACROBiosystems
- 10.8.1 Overview
- 10.8.2 Financial Performance
- 10.8.3 Product Outlook
- 10.8.4 Key Developments
10.9 CellGenix GmBH
- 10.9.1 Overview
- 10.9.2 Financial Performance
- 10.9.3 Product Outlook
- 10.9.4 Key Developments
10.10 RayBiotech Inc.
- 10.10.1 Overview
- 10.10.2 Financial Performance
- 10.10.3 Product Outlook
- 10.10.4 Key Developments